<DOC>
	<DOCNO>NCT00452387</DOCNO>
	<brief_summary>The purpose research study determine combination mitoxantrone , prednisone sorafenib improve time progression advance stage metastatic hormone-refractory prostate cancer .</brief_summary>
	<brief_title>Mitoxantrone , Prednisone Plus Sorafenib Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer ( HRPC )</brief_title>
	<detailed_description>The primary objective study test hypothesis combination Mitoxantrone , Prednisone Sorafenib taxane-refractory patient metastatic hormone refractory prostate cancer ( mHRPC ) result improvement median time progression ( TTP ) . Since median ( i.e 50 % patient ) TTP Mitoxantrone/Prednisone 3 month , hypothesis 70 % progress 3 month investigational combination . Progression assess radiologic imaging criterion . The early stopping point 21 subject . If 10 few subject tumor favorable response observe 21 subject accrue null hypothesis accept trial terminate . If 16 subject tumor favorable response observe 21 subject accrue alternative hypothesis accept trial terminate . The probability early stop null 0.51 , alternative 0.39 . If trial progress 42 subject evaluate 24 subject favorable response observe null hypothesis reject . This design minimize average sample number null , 31.2 .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Voluntary write informed consent Histopathologic diagnosis prostatic adenocarcinoma evidence progression despite adequate castration ( testosterone &lt; 50 ng/dL ) Progressive disease taxanebased chemotherapy ( docetaxel paclitaxel , single agent combination regimen , weekly every 21 day schedule ) Patients discontinue taxane base chemotherapy toxicity eligible long evidence progressive disease Minimum 4 week period last chemotherapy infusion registration ( apply steroid use permit ) . Estramustine need discontinue least 6 week prior first day treatment protocol A minimum 4 week bicalutamide , nilutamide , megestrol acetate ketoconazole , diethylstilbestrol ( DES ) . Minimum 2 week flutamide Reductase inhibitor allow initiate least 2 month prior registration No concurrent investigational therapy Complementary Alternative Medicine ( CAM ) product permit long patient receive least 2 month . Initiation new CAM product protocol discourage . Ongoing androgen deprivation therapy ( orchiectomy , gonadotropinreleasing hormone ( GnRH ) agonist antagonist ) Adequate bone marrow , liver renal function assess follow : Hemoglobin ≥ 9.0 g/dl Absolute neutrophil count ( ANC ) ≥ 1,500/mm3 Platelet count ≥ 100,000/mm3 Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) ALT AST ≤ 2.5 time ULN ( ≤ 5 x ULN patient liver involvement ) Creatinine ≤ 1.5 time ULN International normalize ratio ( INR ) &lt; 1.5 Prothrombin ( PT ) /Partial thromboplastin time ( PTT ) within normal limit . Patients receive anticoagulation treatment agent warfarin heparin may allow participate . For patient warfarin , INR measure prior initiation sorafenib monitor least weekly , define local standard care , INR stable . ECOG performance status ≤ 2 Baseline leave ventricular ejection fraction ( LVEF ) ≥ 50 % Life expectancy ≥ 3 month Patients must agree use adequate contraception prior study entry , study least three month last administration sorafenib More one line prior cytotoxic chemotherapy metastatic setting , previous adjuvant chemotherapy allow No active malignancy prostate cancer ( except nonmelanoma skin cancer ) within 5 year enrollment Known brain metastasis Cardiac disease : Congestive heart failure &gt; class II New York Heart Association ( NYHA ) . Patients must unstable angina new onset angina ( begin within last 3 month ) myocardial infarction within past 6 month Cardiac ventricular arrhythmia require antiarrhythmic therapy Uncontrolled hypertension Active clinically serious infection &gt; Common Terminology Criteria Adverse Events ( CTCAE ) Grade 2 Thrombolic embolic event cerebrovascular accident include transient ischemic attack within past 6 month Pulmonary hemorrhage/bleeding event ≥ CTCAE Grade 2 within 4 week first dose study drug Any hemorrhage/bleeding event ≥ CTCAE Grade 3 within 4 week first dose study drug Poorly control hyperglycemia Treatment radiotherapy within 4 week treatment radiopharmaceutical within past 8 week Patient receive investigational drug within 14 day enrollment Serious medical psychiatric illness likely interfere participation clinical study Serious nonhealing wound ulcer Evidence history bleed diathesis coagulopathy Use St. John 's Wort rifampin Known suspect allergy sorafenib agent give course trial Any condition impair patient 's ability swallow whole pill Any malabsorption problem</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Prostate Cancer</keyword>
</DOC>